Aprea Therapeutics | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.848 K

Revenue: As of FY2025 Q3, the actual value is USD 1.848 K, beating the estimate of USD 0.

EPS: As of FY2025 Q3, the actual value is USD -0.47, missing the estimate of USD -0.34.

EBIT: As of FY2025 Q3, the actual value is USD -3.268 M.

Grant revenue for the three months ended September 30, 2025 was $1,848, compared to $354,621 for the same period in 2024, showing a decrease of $352,773.
Grant revenue for the nine months ended September 30, 2025 was $282,422, compared to $1,296,764 for the same period in 2024, showing a decrease of $1,014,342.

Net Loss: For the three months ended September 30, 2025, the net loss was $2,972,410, compared to $3,783,769 for the same period in 2024, showing an improvement of $811,359.
Net Loss: For the nine months ended September 30, 2025, the net loss was $10,143,939, compared to $10,063,912 for the same period in 2024, showing a slight increase of $80,027.
Research and Development Expenses: For the three months ended September 30, 2025, research and development expenses were $1,638,917, compared to $2,846,399 for the same period in 2024, showing a decrease of $1,207,482.
Research and Development Expenses: For the nine months ended September 30, 2025, research and development expenses were $6,034,196, compared to $7,004,451 for the same period in 2024, showing a decrease of $970,255.
General and Administrative Expenses: For the three months ended September 30, 2025, general and administrative expenses were $1,480,319, compared to $1,605,238 for the same period in 2024, showing a decrease of $124,919.
General and Administrative Expenses: For the nine months ended September 30, 2025, general and administrative expenses were $4,838,969, compared to $5,385,923 for the same period in 2024, showing a decrease of $546,954.

Net Cash Used in Operating Activities: For the nine months ended September 30, 2025, net cash used in operating activities was $9,933,147, compared to $10,045,814 for the same period in 2024.
Net Cash Provided by Financing Activities: For the nine months ended September 30, 2025, net cash provided by financing activities was $798,668, compared to $14,687,490 for the same period in 2024.

Core Business Focus: The company is focused on advancing its clinical-stage product candidates, APR-1051 and ATRN-119, with plans to accelerate dose escalation for APR-1051 and explore combination approaches for ATRN-119.
Non-Core Business: The company is considering further development of ATRN-119 in combination approaches, including radiation therapy and immune checkpoint inhibitors, and is exploring investigator-led studies for combination therapies.
Priority: The company is seeking additional funding to support its operations and has concluded that substantial doubt exists about its ability to continue as a going concern without securing additional financing.